SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:gup.ub.gu.se/294758"
 

Search: id:"swepub:oai:gup.ub.gu.se/294758" > Improvement in the ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Ozcan, MehmetKTH,Science for Life Laboratory, SciLifeLab,Hacettepe University, Ankara, 06100, Turkey (author)

Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-04-08
  • Wiley,2020

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/294758
  • https://gup.ub.gu.se/publication/294758URI
  • https://doi.org/10.1002/adbi.202000030DOI
  • https://research.chalmers.se/publication/517878URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-274016URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • QC 20200629
  • Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death primarily due to the lack of effective targeted therapies. Despite the distinct morphological and phenotypic patterns of HCC, treatment strategies are restricted to relatively homogeneous therapies, including multitargeted tyrosine kinase inhibitors and immune checkpoint inhibitors. Therefore, more effective therapy options are needed to target dysregulated metabolic and molecular pathways in HCC. Integrative genomic profiling of HCC patients provides insight into the most frequently mutated genes and molecular targets, including telomerase reverse transcriptase, the TP53 gene, and the Wnt/β-catenin signaling pathway oncogene (CTNNB1). Moreover, emerging techniques, such as genome-scale metabolic models may elucidate the underlying cancer-specific metabolism, which allows for the discovery of potential drug targets and identification of biomarkers. De novo lipogenesis has been revealed as consistently upregulated since it is required for cell proliferation in all HCC patients. The metabolic network-driven stratification of HCC patients in terms of redox responses, utilization of metabolites, and subtype-specific pathways may have clinical implications to drive the development of personalized medicine. In this review, the current and emerging therapeutic targets in light of molecular approaches and metabolic network-based strategies are summarized, prompting effective treatment of HCC patients. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Altay, ÖzlemKTH,Science for Life Laboratory, SciLifeLab(Swepub:kth)u1g32ner (author)
  • Lam, S.King's College London (author)
  • Turkez, H.Atatürk Üniversitesi,Atatürk University (author)
  • Aksoy, Y.Hacettepe Üniversitesi,Hacettepe University (author)
  • Nielsen, Jens B,1962Chalmers tekniska högskola,Chalmers University of Technology(Swepub:cth)nielsenj (author)
  • Uhlén, MathiasKTH,Science for Life Laboratory, SciLifeLab(Swepub:kth)u1dulvmw (author)
  • Borén, Jan,1963Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,University of Gothenburg(Swepub:gu)xborej (author)
  • Mardinoglu, Adil,1982KTH,Science for Life Laboratory, SciLifeLab,Craniofacial Sciences, King’s College London, London(Swepub:kth)u1t8kmr6 (author)
  • KTHScience for Life Laboratory, SciLifeLab (creator_code:org_t)

Related titles

  • In:Advanced Biosystems: Wiley4:62366-7478

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view